Recordati Ireland Limited

Sanofi

Recordati S.a. Chemical and Pharmaceutical Company

Recordati S.a.

Recordati, S.a., Chemical and Pharmacueticals Company

Elena Poggesi

Carlo Riva

Amedeo Leonardi

Gianni Motta

Davide Graziani

Patrizia Angelico

Carlo De Toma

Robert Boigegrain

Roberto Cecchi

Tiziano Croci

Alberto Bianchetti

Luciano Guarneri

Matteo Longhi

Matteo Marco Longhi

This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.

Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors

This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).

Heterocyclic derivatives as M-GLU5 antagonists

The invention relates to novel N-(substituted phenyl)-N&prime;-&lsqb;&ohgr;-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl&rsqb;piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.

Isoxazolecarboxamide derivatives

The invention relates to novel N-(substituted phenyl)-N&prime;-&lsqb;&ohgr;-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl&rsqb;piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions.

Disclosed herein are novel compounds and methods for the treatment of disorders of the lower urinary tract. The novel compounds are 1,4-disubstituted piperazine derivatives. The methods comprise the administration of the novel compounds of the invention, and other compounds that bind to 5HT,receptors, for treating disorders of the lower urinary tract.

1,4-disubstituted piperazines

A novel phenylethanolaminotetraline having lipolytic activity of formula ##STR1## wherin X represents hydrogen, halogen, a trifluoromethyl or a lower alkyl group and R represents hydrogen, a lower alkyl group not substituted or substituted by a cycloalkyl group containing 3 to 7 carbon atoms, a hydroxy group, a lower alkoxy, carboxy or lower carbalkoxy group; a cycloalkyl group containing 3 to 7 carbon atoms; or a lower alcanoyl group; or a pharmaceutically acceptable salt thereof; a process for its preparation; and pharmaceutical compositions containing it as active ingredient, useful for the treatment of obesity.

Phenylethanolaminotetralines, a process for their preparation and

Growing community of inventors

Milan, Italy

Elena Poggesi